Skip to main content
TipRanks
Go Ultimate75% OFF

Exelixis (EXEL) Revenue by Segment

3,215 Followers

Revenue by Segment

In Q3 2026, Exelixis reported revenue by segment of $53.77M (Collaboration), $603.15M (Cabometyx) and $1.77M (Cometriq).

Separates revenue into categories like product sales, royalties/collaborations, and other income. For Exelixis, segment-level detail highlights reliance on flagship oncology products versus partner payments, indicating concentration risk, recurring royalty stability, and sensitivity to clinical or patent events.

$0.00$250.00M$500.00M$750.00M$1.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

CABOMETYX is unmistakably the growth engine, delivering sustained, accelerating net‑product revenue while Cometriq and Collaboration are small and lumpy (that Collaboration spike appears one‑off). Management’s guidance trim reflects a slower NET uptake and higher gross‑to‑net deductions—meaning demand looks intact but near‑term realized revenue will be modestly constrained. Low trade inventory and large buybacks signal cash strength and confidence, but the stock’s upside hinges on executing the NET ramp and successful zanzalintinib readouts to diversify reliance on cabozantinib.

EXEL Revenue by Segment

PeriodCollaborationCabometyxCometriqUnited States
Q3 2026Sep 30, 2026$53.77M$603.15M$1.77M―
Q2 2026Jun 30, 2026$55.66M$570.65M$2.38M―
Q1 2026Mar 31, 2026$55.84M$552.77M$2.20M―
Q4 2025Dec 31, 2025$52.09M$544.73M$1.85M―
Q3 2025Sep 30, 2025$54.83M$539.88M$3.05M―
Q2 2025Jun 30, 2025$48.25M$517.89M$2.12M―
Q1 2025Mar 31, 2025$42.16M$510.87M$2.41M$517.18M
Q4 2024Dec 31, 2024$51.51M$512.84M$2.46M$519.09M
Q3 2024Sep 30, 2024$61.50M$475.70M$2.40M$481.50M
Q2 2024Jun 30, 2024$199.60M$433.30M$4.20M$440.50M
Q1 2024Mar 31, 2024$46.70M$376.40M$2.10M$381.90M
Q4 2023Dec 31, 2023$50.30M$427.70M$1.60M$432.70M
Q3 2023Sep 30, 2023$45.40M$422.20M$4.30M$429.60M
Q2 2023Jun 30, 2023$60.20M$403.30M$6.40M$416.00M
Q1 2023Mar 31, 2023$45.40M$361.80M$1.60M$367.40M
Q4 2022Dec 31, 2022$46.50M$372.60M$4.90M$380.60M
Q3 2022Sep 30, 2022$45.30M$361.40M$5.10M$369.50M
Q2 2022Jun 30, 2022$72.40M$339.20M$7.90M$349.60M
Q1 2022Mar 31, 2022$45.70M$302.80M$7.50M$314.10M
Q4 2021Dec 31, 2021$148.50M$295.10M$7.60M$305.80M
Q3 2021Sep 30, 2021$65.30M$259.80M$3.30M$266.40M
Q2 2021Jun 30, 2021$100.90M$275.60M$8.60M$287.20M
Q1 2021Mar 31, 2021$43.00M$223.60M$3.60M$230.00M
Q4 2020Dec 31, 2020$69.70M$196.30M$4.00M$203.50M
Q3 2020Sep 30, 2020$62.50M$159.60M$9.00M$171.60M
Q2 2020Jun 30, 2020$80.70M$173.60M$5.10M$181.20M
Q1 2020Mar 31, 2020$33.00M$189.20M$4.70M$196.60M
Q4 2019Dec 31, 2019$45.40M$181.10M$13.80M$197.30M

Related KPIs